Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas

Annals of Oncology

Volumn 17, Issue 4, 2006, Pages 646-651

  Leyvraz, Serge ^a   Zweifel, M ^a   Jundt, G ^b   Lissoni, A ^c   Cerny, T ^d   Sessa, C ^e   Fey, M ^f   Dietrich, D ^g   Honegger, H P ^h  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c SAN GERARDO HOSPITAL   (Italy)

^d Istituto Oncologico della Svizzera italiana ^*  (Italy)

^e REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^f UNIVERSITY OF BERN   (Switzerland)

^g City Hospital Triemli ^*  (Italy)

^h TRIEMLI HOSPITAL   (Switzerland)

Author keywords

Doxorubicin; Endometrial stromal sarcomas; Gynecologic sarcomas; Ifosfamide; Leiomyosarcomas; Mixed mesodermal tumors

Indexed keywords

DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MESNA; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FATALITY; DRUG MEGADOSE; ENDOMETRIUM SARCOMA; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GYNECOLOGIC CANCER; HEART FAILURE; HEMATURIA; HUMAN; INFECTION; LEIOMYOSARCOMA; LONG TERM CARE; METASTASIS; MIXED MULLERIAN TUMOR; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SALVAGE THERAPY; SARCOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; IFOSFAMIDE; NEOPLASM METASTASIS; SARCOMA; SURVIVAL ANALYSIS;

EID: 33645314364     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl020     Document Type: Article

References (34)

1. Amant F, Vloeberghs V, Woestenborghs H et al. Transition of epithelial toward mesenchymal differentiation during ovarian carcinosarcoma tumorigenesis. Gynecol Oncol 2003; 90: 372-377.
2. Rose PG, Piver MS, Tsukada Y et al. Patterns of metastasis in uterine sarcoma. An autopsy study. Cancer 1989; 63: 935-938.
3. Blay JY, van Glabbeke M, Verweij J et al. Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer 2003; 39: 64-69.
4. Sutton GP, Blessing JA, Barrett RJ et al. Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: A Gynecologic Oncology Group study. Am J Obstet Gynecol 1992; 166: 556-559.
5. Sutton G, Blessing JA, Park R et al. Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: A study of the Gynecologic Oncology Group. Obstet Gynecol 1996; 87: 747-750.
6. Omura GA, Major FJ, Blessing JA et al. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 1983; 52: 626-632.
7. Sutton G, Blessing JA, Malfetano JH. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcomas of the uterus: A Gynecologic Oncology Group study. Gynecol Oncol 1996; 62: 226-229.
8. Campos SM, Matulonis UA, Penson RT et al. Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Mullerian tumors. Gynecol Oncol 2003; 90: 610-618.
9. Hensley ML, Maki R, Venkatraman E et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: Results of a phase II trial. J Clin Oncol 2002; 20: 2824-2831.
10. Kanjeekal S, Chambers A, Fung Kee Fung M et al. Systemic therapy for advanced uterine sarcoma: A systematic review of the literature. Gynecol Oncol 2005; 97: 624-637.
11. Frustaci S, Buonadonna A, Galligioni E et al. Increasing 4′-epidoxorubicin and fixed ifosfamide doses plus granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A pilot study. J Clin Oncol 1997; 15: 1418-1426.
12. Cerny T, Leyvraz S, von Briel T et al. Saturable metabolism of continuous high-dose ifosfamide with mesna and GM-CSF: A pharmacokinetic study in advanced sarcoma patients. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 1999; 10: 1087-94.
13. Patel SR, Vadhan-Raj S, Papadopolous N et al. High-dose ifosfamide in bone and soft tissue sarcomas: Results of phase II and pilot studies - dose-response and schedule dependence. J Clin Oncol 1997; 15: 2378-2384.
14. 2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. J Clin Oncol 2005; 23: 105-112.
15. Le Cesne A, Judson I, Crowther D et al. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2000; 18: 2676-2684.
16. Leyvraz S, Bacchi M, Cerny T et al. Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK). Ann Oncol 1998; 9: 877-884.
17. Maki RG. Multidisciplinary management of soft-tissue sarcomas. Cancer Invest 2002; 20: 818-824.
18. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
19. Castellanos AM, Fields WS. Grading of neurotoxicity in cancer therapy. J Clin Oncol 1986; 4: 1277-1278.
20. Kupfer A, Aeschlimann C, Wermuth B et al. Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue. Lancet 1994; 343: 763-764.
21. Sutton GP, Blessing JA, Rosenshein N et al. Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study). Am J Obstet Gynecol 1989; 161: 309-312.
22. Sutton GP, Blessing JA, Homesley HD et al. A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemotherapy: A Gynecologic Oncology Group study. Gynecol Oncol 1994; 53: 24-26.
23. Piver MS, Lele SB, Patsner B et al. Melphalan, 5-fluorouracil, and medroxyprogesterone acetate in metastatic endometrial carcinoma. Obstet Gynecol 1986; 67: 261-264.
24. Blum RH, Edmonson J, Ryan L et al. Efficacy of ifosfamide in combination with doxorubicin for the treatment of metastatic soft-tissue sarcoma. The Eastern Cooperative Oncology Group. Cancer Chemother Pharmacol 1993; 31 (Suppl 2): S238-S240.
25. Schutte J, Mouridsen HT, Stewart W et al. Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 1990; 26: 558-561.
26. Benjamin RS. Grade 3 nausea, vomiting, and myelosuppression or progressive, metastatic sarcoma? J Clin Oncol 1987; 5: 833-835.
27. Patel SR, Vadhan-Raj S, Burgess MA et al. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol 1998; 21: 317-321.
28. Reichardt P, Tilgner J, Hohenberger P et al. Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: A phase II study. J Clin Oncol 1998; 16: 1438-1443.
29. Maurel J, Fra J, Lopez-Pousa A et al. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: A Phase II trial by the Spanish Group for Research on Sarcomas (GEIS). Cancer 2004; 100: 1498-1506.
30. Billingsley KG, Lewis JJ, Leung DH et al. Multifactorial analysis of the survival of patients with distant metastasis arising from primary extremity sarcoma. Cancer 1999; 85: 389-395.
31. Maurel J, Buesa J, Lopez-Pousa A et al. Salvage surgical resection after high-dose ifosfamide (HDIF) based regimens in advanced soft tissue sarcoma (ASTS): A potential positive selection bias - a study of the Spanish group for research on sarcomas (GEIS). J Surg Oncol 2004; 88: 44-49.
32. Billingsley KG, Burt ME, Jara E et al. Pulmonary metastases from soft tissue sarcoma: Analysis of patterns of diseases and postmetastasis survival. Ann Surg 1999; 229: 602-612.
33. Levenback C, Rubin SC, McCormack PM et al. Resection of pulmonary metastases from uterine sarcomas. Gynecol Oncol 1992; 45: 202-205.
34. Leitao MM, Brennan MF, Hensley M et al. Surgical resection of pulmonary and extrapulmonary recurrences of uterine leiomyosarcoma. Gynecol Oncol 2002; 87: 287-294.